Cargando…

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Martino, Gabriella, Catalano, Antonino, Agostino, Rita Maria, Bellone, Federica, Morabito, Nunziata, Lasco, Carmen Giulia, Vicario, Carmelo Mario, Schwarz, Peter, Feldt-Rasmussen, Ulla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098625/
https://www.ncbi.nlm.nih.gov/pubmed/32214378
http://dx.doi.org/10.1371/journal.pone.0230681
_version_ 1783511214893039616
author Martino, Gabriella
Catalano, Antonino
Agostino, Rita Maria
Bellone, Federica
Morabito, Nunziata
Lasco, Carmen Giulia
Vicario, Carmelo Mario
Schwarz, Peter
Feldt-Rasmussen, Ulla
author_facet Martino, Gabriella
Catalano, Antonino
Agostino, Rita Maria
Bellone, Federica
Morabito, Nunziata
Lasco, Carmen Giulia
Vicario, Carmelo Mario
Schwarz, Peter
Feldt-Rasmussen, Ulla
author_sort Martino, Gabriella
collection PubMed
description INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs). PURPOSE: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis. METHODS: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected. RESULTS: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (p<0.05 for all). After 6 months of treatment with AIs, BCSs showed significant reduction of anxious and depressive symptoms and a significantly higher perceived QoL for both physical and mental components, vs. controls. CONCLUSIONS: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs.
format Online
Article
Text
id pubmed-7098625
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70986252020-04-03 Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer Martino, Gabriella Catalano, Antonino Agostino, Rita Maria Bellone, Federica Morabito, Nunziata Lasco, Carmen Giulia Vicario, Carmelo Mario Schwarz, Peter Feldt-Rasmussen, Ulla PLoS One Research Article INTRODUCTION: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs). PURPOSE: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis. METHODS: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected. RESULTS: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (p<0.05 for all). After 6 months of treatment with AIs, BCSs showed significant reduction of anxious and depressive symptoms and a significantly higher perceived QoL for both physical and mental components, vs. controls. CONCLUSIONS: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs. Public Library of Science 2020-03-26 /pmc/articles/PMC7098625/ /pubmed/32214378 http://dx.doi.org/10.1371/journal.pone.0230681 Text en © 2020 Martino et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Martino, Gabriella
Catalano, Antonino
Agostino, Rita Maria
Bellone, Federica
Morabito, Nunziata
Lasco, Carmen Giulia
Vicario, Carmelo Mario
Schwarz, Peter
Feldt-Rasmussen, Ulla
Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
title Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
title_full Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
title_fullStr Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
title_full_unstemmed Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
title_short Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
title_sort quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098625/
https://www.ncbi.nlm.nih.gov/pubmed/32214378
http://dx.doi.org/10.1371/journal.pone.0230681
work_keys_str_mv AT martinogabriella qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT catalanoantonino qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT agostinoritamaria qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT bellonefederica qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT morabitonunziata qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT lascocarmengiulia qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT vicariocarmelomario qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT schwarzpeter qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer
AT feldtrasmussenulla qualityoflifeandpsychologicalfunctioninginpostmenopausalwomenundergoingaromataseinhibitortreatmentforearlybreastcancer